雅克抑制剂和克罗恩氏病的作用
Mengyan Xu1, Shi Wang2, Sanping Xu1
1Health Management Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Biomedicines
|June 26, 2025
概括
口服JAK抑制剂为克罗恩病提供向治疗,但疗效和安全性各不相同. 乌帕达西提尼布显示出有希望的结果,而对副作用的担忧需要在管理这种炎症性肠道疾病时谨慎使用.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 克罗恩氏病是一种慢性炎症性胃肠道疾病,全球发病率不断增加.
- 生物药物改善了治疗,但有局限性;口服小分子药物正在出现.
- 简氏激酶 (JAK) 抑制剂针对克罗恩病治疗中的JAK/STAT通路.
研究的目的:
- 为了审查克罗恩病的病理生理学.
- 评估JAK抑制剂在克罗恩病管理中的有效性和安全性.
- 为指导临床实践和对克罗恩病JAK抑制剂的未来研究.
主要方法:
- 对现有文献进行系统审查.
- 对JAK抑制剂 (托法西提尼布,菲尔戈提尼布,乌帕达西提尼布) 的临床试验数据的分析.
- 评估疗效,安全性概况和治疗结果.
主要成果:
- 托法西提尼布对克罗恩病的疗效有限.
- 菲尔戈提尼布在最初的试验中显示出有前途,但在后来的试验中缺乏一致的内镜改善.
- 在第二阶段试验中,upadacitinib取得了显著的缓解率,但长期安全数据至关重要.
结论:
- 雅克抑制剂代表了克罗恩病的有前途的治疗类.
- 乌帕达西替尼显示出潜力,但必须仔细考虑安全风险 (血栓栓塞,感染,恶性瘤).
- 需要进一步的研究来优化JAK抑制剂的使用,并解决克罗恩病管理中的安全问题.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
240
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
240
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
278
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
278
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
210
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
210
Inflammatory Bowel Disease IV: Pharmacological Management
204
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
204
Inflammatory Bowel Disease II: Crohn's Disease
401
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
401
Drugs for Treatment of Ulcerative Colitis in IBD
244
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
244


